Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)

NCT ID: NCT05427669

Last Updated: 2022-10-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 340 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-09
• Study Completion Date: 2027-07-01

Brief Summary

Surgery is the main treatment method for colon cancer. About 50% of patients can be cured with surgery alone. For colon cancer with high-risk stage II or III after surgery, the current guidelines recommend 3-6 months after surgery. adjuvant chemotherapy to reduce the risk of recurrence and metastasis. However, for this part of the population, the overall benefit of adjuvant chemotherapy is limited, and different high-risk factors have different weights; some patients will still experience recurrence and metastasis even after receiving adjuvant chemotherapy. A number of previous studies have shown that patients with a positive ctDNA test on postoperative liquid biopsy without postoperative adjuvant therapy have a recurrence risk of 70-80%. Even if they receive adjuvant chemotherapy, the recurrence risk is significantly higher than that of ctDNA-negative patients. ctDNA has received increasing attention as a predictor of postoperative recurrence risk.

This study intends to randomly assign 1:1 to mFOLFOXIRI regimen adjuvant chemotherapy for 6 months and mFOLFOX6 regimen for colon cancer patients with postoperative high-risk stage II-III and liquid biopsy results within 1 month after surgery. Adjuvant chemotherapy was performed for 6 months, ctDNA was dynamically monitored after 3 months of treatment and at the end of adjuvant therapy. During the follow-up period, CEA was reviewed every 3 months, and chest, abdomen, and pelvis CT and ctDNA were reviewed every 6 months; the primary endpoint of the study was 2 years RFS, secondary endpoints included 3-year DFS, OS, safety and tolerability. Through intensive postoperative adjuvant therapy, we hope to screen colon cancer patients with high recurrence risk to receive adjuvant chemotherapy and improve the survival prognosis of ctDNA-positive colon cancer patients.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

mFOLFOXIRI

Patients will receive mFOLFOXIRI chemotherapy once every two weeks for at the most 12 cycles as adjuvant therapy

Group Type: EXPERIMENTAL

mFOLFOXIRI

Intervention Type: DRUG

mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most

mFOLFOX6

Patients will receive mFOLFOX6 chemotherapy once every two weeks for at the most 12 cycles as adjuvant therapy

Group Type: ACTIVE_COMPARATOR

mFOLFOX6

Intervention Type: DRUG

mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most

Interventions

mFOLFOXIRI

mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most

Intervention Type: DRUG

mFOLFOX6

mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most

Intervention Type: DRUG

Other Intervention Names

Oxaliplatin; Irinotecan; 5-Fluorouracil; Leucovorin; Oxaliplatin; 5-Fluorouracil; Leucovorin

Eligibility Criteria

Inclusion Criteria

1. Age 18-70 years old

2. Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.

3. ECOG performance status 0-1

4. Upfront surgery (R0 resection) and postoperative pathological stage II -III and the circulating tumor DNA (ctDNA) test results show that MRD was positive

5. Randomization must be within 8 weeks after surgery.

6. No distant metastasis after surgery

7. Appropriate organ function

Exclusion Criteria

1. Postoperative CT scan showed distant meatstasis

2. Patients with postoperative obstruction or active bleeding

3. Other active malignant tumors in the past or at the same time (except for malignant tumors that have received curative treatment and have no disease for more than 5 years or carcinoma in situ that can be cured by adequate treatment)

4. The time from postoperative to start of adjuvant therapy has exceeded 8 weeks

5. Patients who have received neoadjuvant therapy

6. Active coronary artery disease, severe/unstable angina or newly diagnosed angina or myocardial infarction within 12 months prior to study participation

7. Thrombotic or embolic events within the past 6 months, such as cerebrovascular accident (including transient ischemic attack), pulmonary embolism, deep vein thrombosis

8. Unstable or any medical condition that affects patient safety and study compliance

9. Subjects with known allergy to the study drugs or to any of its excipients.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yanhong Deng

OTHER

Sponsor Role: lead

Responsible Party

Yanhong Deng

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Yanhong Deng, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Sixth Affiliated Hospital, Sun Yat-sen University

Central Contacts

Yanhong Deng, Ph.D.

Role: CONTACT

dengyanh@mail.sysu.edu.cn

008613925106525

Jianwei Zhang, Ph.D.

Role: CONTACT

zhangjw25@mail.sysu.edu.cn

00862013480216906

Other Identifiers

GIHSYSU-24

Identifier Type: -

Identifier Source: org_study_id